In vivo efficacy study of the anti-inflammatory properties of Surolan.
This study evaluated the anti-inflammatory properties of Surolan with the use of a pinna model of inflammation in 80 mice and a randomized complete block design. Within each of 8 blocks, 10 treatments, consisting of different combinations of the constituents of Surolan with and without the prednisolone acetate component, were randomly assigned to the 9-wk-old CD-1 mice. The treatments were administered as a single dose 30 min after pinna inflammation was induced with tetradecanoylphorbol acetate. Ear-skin edema and erythema were assessed and measured 4 and 6 h thereafter. Treatment effects were evaluated with repeated-measures analysis of variance. Inclusion of prednisolone acetate with the Surolan vehicle, either alone or in combination with the nonsteroidal constituents of the suspension, resulted in a significant reduction in mean ear-skin thickness and erythema. The inflammation-reducing properties of prednisolone were not significantly affected by the other components of Surolan.
Bolinder
Anna
A
International Bio-Institute Corporation, Fergus, Ontario.
Cameron
Kelly
K
Faubert
Lynn
L
Wilson
Jeff
J
Aramini
Jeff
J
Hare
Jonathan
J
D000704:Analysis of Variance; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004423:Ear / Q000473:pathology; D005260:Female; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D051379:Mice; D008815:Mice, Inbred Strains; D010032:Otitis Externa / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011897:Random Allocation; D013755:Tetradecanoylphorbol Acetate; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; C009935:prednisolone acetate; D011239:Prednisolone; D013755:Tetradecanoylphorbol Acetate